single invest

ISD-Immunotech

ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients.

ISD-Immunotech has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. ISD-Immunotech is one of more than 500 companies that Accelerace already have accelerated.


Related startups